Table 3. Two and three markers analyses.

Biomarkers	Patients	%	Median PFS months	Hazard ratio	P-value (log-rank test)	Median survival months	Hazard ratio	P-value (log-rank test)
High PTEN loss and high PIK3CA gain
No	45	62	4.27			12.3
Yes	27	38	3.02	2.23	0.002	4.93	2.38	<0.001
Low CEN7/cell, high PTEN loss, and high PIK3CA gain
No	50	69	4.21			12.26
Yes	22	31	2.04	2.54	<0.001	4.34	4.04	<0.001
Low EGFR/CEN7 gain, high PTEN loss, and high PIK3CA gain
No	56	78	4.04			10.4
Yes	16	22	2.04	2.62	0.002	4.93	3.37	<0.001
Low EGFR gain, high PTEN loss, and high PIK3CA gain
No	55	76	4.04			10.36
Yes	17	24	2.04	2.52	0.003	4.93	3.35	<0.001
Wild Type (n=37)
High PTEN loss and high PIK3CA gain
No	20	54	3.55			12.3
Yes	17	46	3.02	1.84	0.09	5.49	2.41	0.012
Low CEN7/cell, high PTEN loss, and high PIK3CA gain
No	24	65	3.35			12.5
Yes	13	35	2.04	2.41	0.02	4.18	6.77	<0.001
Low EGFR/CEN7 gain, high PTEN loss, and high PIK3CA gain
No	27	73	3.35			10.6
Yes	10	27	2.04	1.94	0.098	5.49	3.97	0.001
Low EGFR gain, high PTEN loss, and high PIK3CA gain
No	26	70	3.25			10.64
Yes	11	30	2.04	1.84	0.13	5.49	3.97	0.001
EGFR Mutant (n=15)
High PTEN loss, high PIK3CA gain yes/no
No	12	80	16.31			26.4
Yes	3	20	4.54	5.01	0.02*	5.57	8.14	0.002
Low CEN7/cell, high PTEN loss, and high PIK3CA gain
No	13	87	16.31			26.4
Yes	2	13	9.07	3.07	0.2*	11.5	4.35*	0.07

Abbreviations: CEN7=chromosome 7; EGFR=epidermal growth factor receptor; PFS=progression-free survival; PI3KCA=phosphatidylinositol 3-kinase catalytic subunit alpha; PTEN=phosphatase and tensin homologue.

^*P-values, though statistically significant, are reflective of a small sample size.